Edesa Biotech, Inc. (EDSA)
| Market Cap | 6.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.17M |
| Shares Out | 3.47M |
| EPS (ttm) | -1.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,838 |
| Open | 1.750 |
| Previous Close | 1.750 |
| Day's Range | 1.550 - 1.750 |
| 52-Week Range | 1.550 - 5.990 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+1,113.87%) |
| Earnings Date | Feb 7, 2025 |
About EDSA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic conta... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for EDSA stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
Edesa Biotech Reports Fiscal Year 2024 Results
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Edesa Biotech's Founder Makes Strategic Investment in the Company
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Edesa Biotech Announces Upcoming Conference Schedule
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), whe...
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expecte...
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease...
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea...
Edesa Biotech to Participate in Upcoming Investor Conferences
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea...
Edesa Biotech to Participate in Barclays Global Healthcare Conference
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Edesa Biotech to Participate in Upcoming Dermatology Meetings
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dis...
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dise...
Edesa Biotech Reports Fiscal Year 2023 Results
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di...
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:...
Edesa Biotech to Present at Dermatology Drug Development Summit
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr...
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that He...
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-s...
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitmen...
Edesa Biotech Announces One-for-Seven Reverse Share Split
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseas...
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCE...
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial ...
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the c...
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on ...